Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin

Cancer Investigation

Volumn 27, Issue 6, 2009, Pages 636-640

  Zhao, Shipeng ^a   Cai, Jianhui ^a   Bian, Honglei ^a   Gui, Lin ^a   Zhao, Fa ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Apoptosis; Colon cancer; COX 2 inhibitor

Indexed keywords

BETA CATENIN; CELECOXIB; CYCLOOXYGENASE 2; OXALIPLATIN; SURVIVIN; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; CYCLOOXYGENASE 2 INHIBITOR; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; PLATINUM COMPLEX; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG POTENTIATION; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CELL STRAIN HT29; COLON TUMOR; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BETA CATENIN; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; HT29 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; PYRAZOLES; RNA, MESSENGER; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649976957     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802672738     Document Type: Article

References (16)

1. Tuynman, J.B.; Peppelenbosch, M.P.; Rechel, D.J. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol Hematol 2004, 52, 81-101.
2. Thun, M.J.; Henley, S.J.; Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94, 252-266.
3. Takahashi, T.; Kozaki, K.; Yatabe, Y.; Achiwa, H.; Hida, T. Increased expression of COX-2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol 2002, 21, 177-181. (Pubitemid 34655038)
4. Hase, T.; Yoshimura, R.; Matsuyama, M.; Kawahito, Y.; Wada, S.; Tsuchida, K.; Sano, H.; Nakatani, T. Cyclooxygenase-1 and -2 in human testicular tumours. Eur J Cancer 2003, 39, 2043-2049.
5. Koki, A.T.; Masferrer, J.L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002, 9, 28-35. (Pubitemid 34457338)
6. Fujita, T.; Matsui, M.; Takaku, K.; Uetake, H.; Ichikawa, W.; Taketo, M.M.; Suqihara, K. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998, 58, 4823-4826.
7. Koehne, C.H.; DuBois, R.N. COX-2 inhibition and colorectal cancer. Semin Oncol 2004, 31, 12-21.
8. Nelson, W.J.; Nusse, R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303, 1483-1487. (Pubitemid 38314410)
9. Kim, P.J.; Plescia, J.; Clevers, H.; Fearon, E.R.; Altieri, D.C. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003, 362, 205-209.
10. Zhang, T.; Fields, J.Z.; Ehrlich, S.M.; Boman, B.M. The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 2004, 308, 434-437.
11. Rice, P.L.; Kelloff, J.; Sullivan, H.; Drigers, L.J.; Beard, K.S.; Kuwada, S.; Piazza, G.; Ahnen, D.J. Sulindac metabolites induce caspase- and proteasome-dependent degradation of betacatenin protein in human colon cancer cells. Mol Cancer Ther 2003, 2, 885-892.
12. Chen, T.; Yang, I.; Irby, R.; Shain, K.H.;Wang, H.G.; Quackenbush, J.; Coppola, D.; Cheng, J.Q.; Yeatman, T.J. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res 2003, 63, 4368-4374.
13. Yao, M.; Kargman, S.; Lam, E.C.; Kelly, C.R.; Zheng, Y.; Luk, P.; Kwong, E.; Evans, J.F.; Wolfe, M.M. Inhibition of cyclooxygenase- 2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003, 63, 586-592.
14. Trifan, O.C.; Durham, W.F.; Salazar, V.S.; Horton, J.; Levine, B.D.; Zweifel, B.S.; Davis, T.W.; Masferrer, J.L. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002, 62, 5778-5784.
15. Bresalier, R.S.; Sandler, R.S.; Quan, H.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstan, M.A.; Baron, J.A.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352, 1092-1102.
16. Solomon, S.D.; McMurray, J.J.; Pfeffer, M.A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W.F.; Zauber, A.; Hawk, E.; Bertaqnolli, M.; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352, 1071-1080.